The new research
The aim of the study is to demonstrate the performance of the neuCA15.3 test for monitoring treatment response and/or disease recurrence compared to an FDA cleared CA15-3 test (Roche Elecys CA15-3 II).
Is anyone expecting any significantly different data - we've already been told specificity and sensitivity %'s - what exactly will the new study tell us?
Ann: Trading Halt, page-12
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
57.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $63.40M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 37420 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.5¢ | 12112 | 1 |
View Market Depth
| Last trade - 11.52am 15/08/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |
Day chart unavailable